Back to Search
Start Over
Tumefactive demyelinating lesions during etanercept treatment requiring decompressive hemicraniectomy.
- Source :
-
Multiple Sclerosis Journal . May2013, Vol. 19 Issue 6, p820-823. 4p. 1 Color Photograph. - Publication Year :
- 2013
-
Abstract
- Tumor necrosis factor alpha (TNF-α) is a pro-inflammatory and immunoregulatory cytokine involved in the pathogenesis of several autoimmune disorders. Etanercept, a TNF-α antagonist (anti-TNF-α) acting as a soluble TNF-α receptor, has been associated with neurological demyelinating disorders. This paper aims to report an unusual case showing tumefactive central nervous system (CNS) inflammatory demyelination in a patient in the course of TNF -α antagonist therapy, requiring decompressive hemicraniectomy. This report is based on magnetic resonance imaging (MRI) findings and histology. A biopsy confirmed the inflammatory demyelinating nature of the lesions. The clinical presentation is unusual due to the severity of the disease process, requiring decompressive hemicraniotomy with a clinically favorable outcome. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 13524585
- Volume :
- 19
- Issue :
- 6
- Database :
- Academic Search Index
- Journal :
- Multiple Sclerosis Journal
- Publication Type :
- Academic Journal
- Accession number :
- 87499923
- Full Text :
- https://doi.org/10.1177/1352458512461969